dihexa human data clinical trials Dihexa: Off FDA Category 2,

placebo in adult participants with Type 2 Diabetes who have inadequate glycemic control, aiming to replicate the massive weight loss seen in non-diabetic cohorts

GHK-Cu cycling - typically 30 days on / 14 off or 8 weeks on / 4 off - produces comparable results, reduces cost, limits theoretical copper load and keeps receptor sensitivity fresh

Each vial contains 20mg of lyophilized powder with 99% purity confirmed by HPLC

They are generally not recommended during pregnancy or breastfeeding, for people with a known allergy to any component of the formulation, or for those with certain medical conditions

By disrupting the FOXO4-p53 interaction, it induces p53-mediated apoptosis, effectively clearing these damaged, senescent cells

Are injectable treatments recommended in guidelines